Welcome to Investors.vrtx.com - Investor Relations

investors.vrtx.com

Description: Investor S Vrtx. The Investor Relations website contains information about Vertex Pharmaceuticals's business for stockholders, potential...

Google PR 5

Trustworthiness Good
Avg. Daily Visitors N/A

Child Safety Unknown
Avg. Daily Pageviews N/A

Privacy Good

Investor Relations | Vertex Pharmaceuticals

Investors.vrtx.com: get to the top rated Investor S Vrtx pages and content popular with USA-based Investors.vrtx.com users or check the following digest to find out more. Investors.vrtx.com is a malware-free website without age restrictions, so you can safely browse it. It seems that Investors.vrtx.com team has yet to grow their social media activity, as the major social networks contain little or no materials related to this domain. Investors.vrtx.com is hosted with Akamai Technologies, Inc. in United States. Investor S Vrtx traffic is not yet estimated by Alexa.

Visit investors.vrtx.com

Domain info

Location:	United States
Registrant:	Domain Admin (Vertex Pharmaceuticals Incorporated)
Hosted by:	Akamai Technologies, Inc.
Registrar:	CSC Corporate Domains, Inc.
Subnetworks:	23.48.104.16, 23.48.104.18

Social Media Activities

Facebook likes: -
Twitter mentions: -
Google pluses: -
LinkedIn mentions: -
Pinterest pins: -
StumbleUpon views: -

Web Safety

This website is malware-free.
Status ok

See Google Transparency Report

Sites associated with the same registrant

Whois

Expand

Investors.vrtx.com popular pages to visit

Vertex Receives European Approval for KALYDECO™ (ivacaftor) in Eight Non-G551D Gating Mutations (NASDAQ:VRTX) European Commission has approved KALYDECO™ (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight non-G551D gating mutations in the cystic fibrosis t...

Two 24-Week Phase 3 Studies of Lumacaftor in Combination with Ivacaftor Met Primary Endpoint with Statistically Significant June 24, 2014 Two 24-Week Phase 3 Studies of Lumacaftor in Combination with Ivacaftor Met Primary Endpoint with Statistically Significant Improvements in Lung Function (FEV1) in People with Cystic Fib...

Investor Relations | Vertex Pharmaceuticals The Investor Relations website contains information about Vertex Pharmaceuticals's business for stockholders, potential investors, and financial analysts.